The implantable drug administration device demonstrated feasible continuous doxorubicin delivery with acceptable drug delivery error in a Phase I trial.
No takes yet. Share an insight, caveat, or question.
Continuous doxorubicin delivery via implantable pump appears feasible in Phase I; hypothesis-generating and requires prospective efficacy trials before adoption.
Vogelzang et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: